Progress In Personalized Medicine Is Slower Than Some Had Expected, Partly Because Of The Science And Partly Because Of Insufficient Economic Incentives, Particularly For Investing In Molecular Diagnostics (MDX)
Abstract
Authors
M. Mallinson